Surmodics Q2 EPS Forecast Lowered by Barrington Research

Surmodics, Inc. (NASDAQ:SRDX) – Stock analysts at Barrington Research reduced their Q2 2025 earnings per share estimates for Surmodics in a report issued on Friday, January 31st. Barrington Research analyst M. Petusky now expects that the company will earn $0.00 per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Barrington Research also issued estimates for Surmodics’ Q3 2025 earnings at $0.08 EPS.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

SRDX has been the topic of several other reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research report on Thursday, January 30th. StockNews.com assumed coverage on shares of Surmodics in a report on Monday. They issued a “hold” rating for the company. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Stock Down 1.3 %

NASDAQ SRDX opened at $33.62 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The stock has a market capitalization of $480.77 million, a PE ratio of -33.29 and a beta of 1.20. Surmodics has a 1 year low of $25.17 and a 1 year high of $42.44. The business’s 50-day moving average is $38.47 and its 200 day moving average is $39.00.

Institutional Investors Weigh In On Surmodics

Large investors have recently bought and sold shares of the stock. Modus Advisors LLC purchased a new position in shares of Surmodics in the 4th quarter valued at about $40,000. Quest Partners LLC lifted its position in Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after acquiring an additional 1,071 shares during the period. R Squared Ltd acquired a new stake in Surmodics during the 4th quarter worth approximately $55,000. Longfellow Investment Management Co. LLC acquired a new stake in Surmodics during the 3rd quarter worth approximately $67,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Surmodics during the 2nd quarter worth approximately $229,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Insider Buying and Selling at Surmodics

In related news, CFO Timothy J. Arens sold 7,009 shares of Surmodics stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now owns 70,350 shares in the company, valued at approximately $2,774,604. This trade represents a 9.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 8.90% of the stock is currently owned by company insiders.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).